Stockreport

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Ltd. - American Depositary Shares  (PPBT) 
PDF NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd.("Purple Biotech" [Read more]